Resumen de: WO2024040291A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2024067966A1
The present invention provides methods of treating or preventing chronic intestinal inflammation and/or inflammatory bowel disease (IBD) comprising administering GATA6-AS1 lncRNA to a patient in need thereof.
Resumen de: CN117598978A
The invention discloses oral diagnosis and treatment integrated microgel for colitis as well as a preparation method and application of the oral diagnosis and treatment integrated microgel. The preparation method comprises the following steps: firstly, preparing active oxygen (ROS) response nanogel loaded with drug urolithin A by virtue of an ultrasonic emulsification method, then dispersing the drug-loaded nanogel into a sodium alginate solution containing an ROS response probe, and obtaining the diagnosis and treatment integrated microgel in a calcium chloride solution by virtue of an electrospray technology. The diagnosis and treatment integrated microgel provided by the invention can release the ROS response probe and the ROS response drug-loaded nanogel through oral delivery under the pH environment of colon, performs in-situ imaging diagnosis and inflammation relief on colon focuses, promotes tissue repair and regeneration, and achieves the goal of integration of diagnosis and treatment.
Resumen de: CN117554614A
The invention belongs to the technical field of clinical medicine, and discloses application of a reagent for detecting the expression level of a protein biomarker DPP4 in preparation of a clinical diagnosis kit for Crohn's disease, and when the expression level of the protein biomarker DPP4 in peripheral blood serum of a subject is reduced, it is indicated that the subject suffers from Crohn's disease. In addition, the invention also provides a kit for clinical diagnosis of Crohn's disease, a module for clinical diagnosis of Crohn's disease, and a method for screening drugs for treating Crohn's disease. The CD serum diagnosis marker with high sensitivity and specificity provided by the invention can be used for early diagnosis of CD clinically so as to guide the treatment process of CD clinically, and a new theoretical basis is provided for further explaining the pathophysiology pathogenesis of CD.
Resumen de: CN117604093A
The invention belongs to the technical field of clinical medicine, and discloses application of a reagent for detecting genetic susceptibility gene locus group mutation conditions in preparation of a kit for Crohn disease clinical phenotype screening and medication diagnosis. And judging whether the testee suffers from intestinal stenosis or penetration and whether the testee has no response to treatment by using the biological preparation. The invention discloses a Crohn disease susceptible gene locus set with high sensitivity and specificity, and the Crohn disease susceptible gene locus set can be used for clinical diagnosis of intestinal stenosis and penetration of Crohn disease and the use effect of biological agents, so as to guide the clinical treatment process of Crohn disease. And a new theoretical basis is provided for further explaining the pathophysiology pathogenesis of the Crohn disease.
Resumen de: CN117589906A
The invention relates to the technical field of honey detection, and particularly discloses a jujube flower honey identification method and application. The invention provides a method for identifying jujube flower honey, which comprises the following steps: when honey to be detected contains 4-hydroxyquinoline, 4-hydroxy-8-methoxyquinoline, tesorhol, 2-hydroxyquinoline, 3-indole formaldehyde, eurya japonica A, eurya japonica B, carthamus kidney acid, trans, trans-abscisic acid, cis, trans-abscisic acid, cis, cis, cis-tri-p-coumaroyl spermidine, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, cis, when the to-be-detected honey is detected to be the jujube flower honey when the to-be-detected honey is detected to be the jujube flower honey when the to-be-detected honey is detected to be the jujube flower honey when the to-be-detected honey is detected to be the jujube flower honey when the to-be-detected honey is detected to be the jujube flower honey when the to-be-detected honey is detected to be the jujube flower honey when the to-be-detected honey is detected to be the jujube flower honey. The invention provides a new method for constructing a Chinese date honey authenticity and quality evaluation system, and contributes to the development and research of colitis drugs.
Resumen de: CN117593576A
The invention discloses an image classification method for identifying an inflammatory bowel disease based on detector CT image data. The image classification method comprises the following steps of S1, grouping Crohn disease patients, ulcerative colitis patients and intestinal tuberculosis patients according to clinical data; s2, performing double-layer detector spectrum CT examination on all patients to obtain arterial phase and venous phase data; s3, storing all spectral data in a holographic spectral image data packet, and reconstructing each energy spectrum image on a post-processing workstation; s4, measuring each quantitative parameter of the case by using each module on the post-processing workstation; s5, analyzing each quantitative parameter in the step S4; s6, in combination with various parameters and statistics, the diagnosis efficiency of spectrum CT influence data of the double-layer detector on identification of Crohn's disease, ulcerative colitis and intestinal tuberculosis is assessed, the iodine density value, the standardized iodine density value, the effective atomic number value and the virtual plain scanning value are calculated, and through quantitative index data analysis, the identification accuracy of the three groups of diseases is improved.
Resumen de: WO2024031149A1
The present invention provides methods and kits for the determination of oxidative status and/or the detection of myeloperoxidase in a faecal sample. The methods and kits may find application in diagnosing and/or determining the severity of inflammatory bowel disease (IBD) and/or infectious colitis.La présente invention concerne des procédés et des kits permettant de déterminer l'état oxydatif et/ou de détecter la myéloperoxydase dans un échantillon fécal. Les procédés et les kits peuvent être utilisés pour diagnostiquer et/ou déterminer la gravité d'une maladie inflammatoire de l'intestin (MII) et/ou d'une colite infectieuse.
Resumen de: AU2022321666A1
A method for detecting gastrointestinal permeability in a subject comprises administering a solution comprising lactulose and galactose to the subject. A sample of blood is taken from the subject after administering the solution. A ratio of the concentration of lactulose to the concentration of galactose in the blood sample is an indicator of gastrointestinal permeability.
Nº publicación: US2024053336A1 15/02/2024
Solicitante:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIV [US]
MAYO FOUNDATION FOR MEDICAL EDUCATION & RES [US]
Arizona Board of Regents on Behalf of Arizona State University,
Mayo Foundation for Medical Education & Research
Resumen de: US2024053336A1
The present invention relates anti-microbial antibody signatures of inflammatory bowel disease and their use in early and accurate diagnosis of disease including ulcerative colitis (UC) and Crohn's disease (CD).